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Abstract
Background: The objective of this study was to document the clinical, laboratory and genetic
features of galactosemia in patients from the Cape Town metropolitan region.
Methods: Diagnoses were based on thin layer chromatography for galactosuria/galactosemia and
assays of erythrocyte galactose-1-phosphate uridyltransferase (GALT) and galactokinase activities.
Patients were screened for the common S135L and Q188R transferase gene mutations, using PCR-
based assays. Screening for the S135L mutation in black newborns was used to estimate the carrier
rate for galactosemia in black South Africans.
Results: A positive diagnosis of galactosemia was made in 17 patients between the years 1980 to
2001. All had very low or absent galactose-1-phosphate uridyltransferase (GALT) activity, and
normal galactokinase levels. The mean age at diagnosis was 5.1 months (range 4 days to 6.5
months). A review of 9 patients showed that hepatomegaly (9/9), and splenomegaly, failure to
thrive, developmental delay, bilateral cataracts (6/9) were the most frequent features at diagnosis.
Six had conjugated hyperbilirubinemia. Four experienced invasive E. coli infection before diagnosis.
Ten patients were submitted to DNA analysis. All 4 black patients and 2 of mixed extraction were
homozygous for the S135L allele, while all 3 white patients were homozygous for the Q188R allele.
The remaining patient of mixed extraction was heterozygous for the Q188R allele. The estimated
carrier frequency of the S135L mutation in 725 healthy black newborns was 1/60.
Conclusions:  In the absence of newborn screening the delay in diagnosis is most often
unacceptably long. Also, carrier frequency data predict a galactosemia incidence of approximately
1/14 400 for black newborns in the Cape Metropole, which is much higher than the current
detection rate. It is thus likely that many patients go undetected.
Background
Galactosemia is an autosomally inherited disorder of ga-
lactose metabolism, which occurs as a consequence of a
deficiency of one of three principal enzymes involved in
the metabolism of galactose, through its conversion to
glucose. These enzymes are galactokinase (GALK;
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EC2.7.1.6), galactose-1-phosphate uridyltransferase
(GALT; EC2.7.7.10) and uridine-diphosphate galactose-4'
epimerase (GALE; EC 5.1.3.2). The most common defi-
ciency in all communities is that of the transferase en-
zyme, and it is this enzyme deficiency that underlies
"classical galactosemia"[1].
Transferase-deficiency galactosemia usually presents in
the neonatal period with failure to thrive, feeding difficul-
ties and prolonged conjugated hyperbilirubinemia. The
condition can be fatal if a lactose / galactose restricted diet
is not introduced. Presentation later in life may involve
hepatic cirrhosis, cataracts, ataxia, speech defects, mental
retardation and premature ovarian failure [2]. Laboratory
diagnosis usually proceeds through a demonstration of
galactosuria, an elevated erythrocyte galactose-1-phos-
phate concentration, and reduced / absent erythrocyte
GALT activity.
The laboratories of the Red Cross Children's Hospital
have functioned as an African (Zimbabwe), National and
Western Cape Provincial reference centre for galactosemia
for the past two decades. Of the 41 positive cases record-
ed, 29 (71%) have been black, with the majority of these
patients being born in Zimbabwe. While other laborato-
ries in South Africa also offer galactosemia diagnostics,
virtually all cases investigated in Cape Town and the
broader Cape Metropole region, have involved the Red
Cross Children's Hospital laboratories. All patients were
evaluated with specific red-cell enzyme assays. More re-
cently, patients have been screened for common muta-
tions in the GALT gene. The Cape Metropole surrounds
Cape Town to the east, north and west, and is home to
3.15 million people of diverse ancestries.
This report documents the presenting clinical and labora-
tory features of galactosemia in patients from the Cape
Metropole and describes a rapid polymerase chain reac-
tion (PCR) assay for identifying the S135L mutation. This
assay was successfully used to estimate the carrier frequen-
cy of the S135L mutation in black newborn babies in the
region.
Methods
Patients
All children diagnosed with galactosemia in the Cape
Metropole by the Chemical Pathology laboratories at Red
Cross Children's Hospital between 1980 and 2001 were
identified from the service database. Hospital case records
were retrospectively reviewed to establish the clinical and
laboratory features present at the time of diagnosis.
Galactosuria/galactosaemia
Galactose concentrations in urine and serum/plasma were
examined by thin layer chromatography (TLC). Aliquots
(5 µl) were spotted onto Silica gel plates (Merck Silical Gel
60), developed twice in butanol:acetone:water (5:4:1)
and visualised using the aniline-diphenylamine Phos-
phate reagent [3].
Enzyme assay
EDTA blood (5 ml) was drawn for plasma TLC, and deter-
mination of erythrocyte transferase and kinase activities.
Transferase activity is given as U/gm Hb (1 unit = 1 µmol
UDPG /hr). Both enzyme assays were carried out on cell
lysates, according to established methods [4],[5].
DNA testing
All DNA testing was approved by the Ethics Research
Committee of the University of Cape Town. Mutation
analysis was only carried out for the Q188R [6] and S135L
[7,8] mutations in the GALT gene underlying classical (G/
G) galactosemia. These mutations are commonly reported
in patients of Caucasian, and Negroid ancestries, respec-
tively. Both mutations were detected by PCR using blood
spots prepared from venous or umbilical cord blood sam-
ples. The latter samples were obtained from midwife ob-
stetric units and were anonymised by removing all
identifying tags. Genomic DNA extracts suitable for PCR
were prepared from punched discs (3 mm), which were
treated with methanol (200 µl), air-dried and then boiled
in 50 µl water. Aliquots of 5 µl were used for each PCR de-
termination, in a total volume of 25 µl. A hot start or the
use of antibody inhibited Taq polymerase was required to
obtain consistent and reliable amplification.
Transferase-deficiency galactosemia patients were
screened for the common S135L mutation using a novel
restriction PCR assay where a mismatch forward primer
(P1) was used to introduce a Psh Al cutting site (GAC
N4GTC) into the PCR product derived from the normal al-
lele; P2 was used as the reverse primer. Large scale screen-
ing of the cord blood samples was carried out using a less
costly PCR assay where amplification refractory mutation
system (ARMS) primers were used, these being forward
primers P3 and P4. These primers selectively amplified ei-
ther the mutant or the normal sequence of the GALT al-
lele; two tubes were therefore set up for each cord blood
sample, with P2 again being the reverse primer. The se-
quences of the "in house" primers used in these assays are
as follows:
P1, 5'-ATGTGCTTCCGACCCTGGTC-3';
P2, 5'-GGAAGGGGCGACCTCACAAAC-3';
P3, 5'-TCATGTGCTTCCACCCCTGTTC-3';
P4, 5'-TCATGTGCTTCCACCCCTGTTT-3'.BMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/7
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The common Caucasian mutation, Q188R was detected
by PCR amplification of exon 6 and digestion with the re-
striction enzyme Hpa II as described [9].
Results
Patients
Between 1980 and 2001, 17 patients from the Cape
Metropole were diagnosed with galactosemia; this cohort
included one sib pair. The ancestries of these patients were
recorded as Black (being of Negroid extraction), Mixed
(admixture of European, Negroid and East-Indian extrac-
tion), and White (of European extraction). The mean age
at diagnosis was 5.1 months (range: 4 days to 6.5
months), with the male to female ratio being 1.6 : 1. Eight
children (47%) were black, 3 (18%) were white and 6
(35%) were of mixed ancestry. During the period 1980 to
1989 nine children were diagnosed, from 1990 to 1999
six children were diagnosed and during the last 2 years
two were diagnosed.
The clinical notes of 9 patients were available for review.
These showed hepatomegaly (9/9), and splenomegaly,
failure to thrive, developmental delay, bilateral cataracts
(6/9) to be the most frequently encountered features at
the time of diagnosis (Table 1). One child had a family
history of galactosemia on presentation. Four experienced
invasive E. coli infection before diagnosis. Six had conju-
gated hyperbilirubinemia, 5 elevated plasma alanine ami-
notransferase concentration, 8 elevated alkaline
phosphatase concentration and 7 reduced plasma albu-
min concentration.
Laboratory findings
All patients presented with galactosuria and very low or
absent transferase activity, giving a mean and SD of 2.2 ±
1.12 U/gm Hb (n = 17; range 0–3.8) and normal galac-
tokinase levels. Where possible, blood was also obtained
from the parents to establish transferase levels in obligate
heterozygotes. The range of activities in these subjects (n=
12; mean plus SD = 12.3 ± 3.55 U/gm Hb; range 6.8–
18.2) was distinct from that of the affected cohort but did
show significant overlap with normals (n = 23; mean plus
SD = 31.8 ± 12.9 U/gm Hb; range 12.3–65).
Mutation analysis
Blood spots were available from 10 of the 17 referred pa-
tients, and all were screened using the S135L and Q188R
PCR-based assays. All 4 black patients and 2 patients of
mixed extraction were homozygous for the S135L allele,
while all 3 white patients were homozygous for the
Q188R allele. The remaining patient of mixed extraction
was heterozygous for the Q188R allele and was presumed
to be a compound heterozygote for some other, as yet un-
identified mutation in the GALT gene (Table 2).
Carrier frequency of the S135L mutation
Each of the 725 umbilical cord blood samples generated a
PCR product with the Amplification Refractory Mutation
System (ARMS) primers specific for the normal sequence
at codon 135 of the GALT gene, indicating efficient extrac-
tion of intact DNA template. A total of 12 cord bloods
yielded PCR product with the ARMS primer for the mu-
tant sequence. Carrier status for these individuals was con-
firmed by coupling a repeat ARMs primer PCR with the
restriction PCR assay. These findings yielded a carrier fre-
quency of 1/60 (95% CI; 0.0081 – 0.022).
Discussion
Galactosemia, an inborn error of metabolism, has been
evident in the South African population for many dec-
ades. Only a few reports however, have dealt with the de-
mographics, and clinical / laboratory findings in affected
individuals [10],[11],[12]. The recent unravelling of the
molecular genetics of galactosemia [for review see [13]]
has prompted a re-examination of this condition in South
Africa. This manuscript details the clinical, laboratory and
molecular genetic findings of patients from the Cape Met-
ropolitan region.
The diagnosis of galactosemia is usually made early in the
neonatal period [1]. In the present study, the mean age at
diagnosis of 5.1 months is indicative of considerable de-
lays in detection. While obvious reasons for this are not
apparent, a lack of awareness is likely to be an important
consideration. In summary then, it is important that the
diagnosis be considered in young children with suggestive
features including persistent hypoglycaemia, failure to
thrive, feeding difficulties, prolonged conjugated hyperbi-
lirubinemia, hepatomegaly, ascites, invasive E. coli infec-
tions, neurodevelopmental delay and galactosuria.
Another consideration is that mild clinical phenotypes
Table 1: Clinical features at diagnosis
Clinical feature Number N = 9
Hepatomegaly 9
Splenomegaly 6
Failure to thrive 6
Developmental delay 6
Bilateral cataracts 6
Jaundice 5
Underweight-for-age 5
Stunting 4
Vomiting 2
Ascites 1
Diarrhoea 1BMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/7
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may delay presentation. In contrast to the Q188R muta-
tion, the S135L mutation is associated with a better clini-
cal outcome [8].
Treatment of Galactosemia involves complete elimina-
tion of dietary lactose / galactose. This limits death associ-
ated with E. coli infection, reverses growth failure and
cataract formation, and prevents severe liver disease. Un-
fortunately, dietary modification does not moderate the
risk of long-term central nervous system dysfunction such
as speech defects, mental retardation and ataxia nor pre-
mature ovarian failure [2],[14],[15].
The GALT genotypes defined in our patient cohort con-
form to reports from other countries, where the Q188R
and S135L mutations are commonly encountered in clas-
sical galactosemia. Allele prevalences of 60–70% have
been found for Q188R in Caucasian patients [16,17],
while prevalences of 48% [8] and 91% [12], have been re-
ported in African American and in African Negroid pa-
tients, respectively. Of the 18 GALT alleles, from the 9
unrelated patients in our study, only one did not carry ei-
ther of these two mutations. Although our sample size is
small, this finding holds great promise for the genetic di-
agnosis of galactosemia in South Africa, as these two mu-
tations alone will account for the bulk of the galactosemia
burden. While other prominent mutations have been de-
scribed, such as the K285N substitution in East / Central
Europe, the majority of the mutations listed in the GALT
database (URL:  [http://www.ich.bris.ac.uk/galtdb/]) are
rare and likely to be family specific. All 10 of the black
GALT alleles examined in our study carried the S135L
amino acid substitution. This finding confirms the earlier
report of a >90% association of this mutation with GALT
alleles in black South Africans [12]. In contrast, the two
unrelated white patients were both homozygous for the
Q188R mutation. It is not surprising therefore, that 5 of
the 6 GALT alleles from patients of mixed ancestry, mani-
fest one of these two mutations.
The true incidence of galactosemia in South Africa re-
mains difficult to define. Newborn screening and other
surveillance programmes in Europe and North America
have established newborn rates of 1/30 000 to 1/ 50 000
in Caucasians [18],[19,20]. Similar newborn incidences
are probably present in white South Africans. A reliable
figure can now be applied to black South Africans as our
cord-blood screening programme for the S135L mutation
in the GALT gene has yielded a carrier frequency of 1/60
in this population grouping. Given that >90% of galactos-
emia in this group is associated with this mutation, a new-
born incidence of approximately 1/14 400 can be
expected in the Cape Metropolitan region. This is in ac-
cord with the S135L carrier frequency data from the
Northern regions of South Africa, which suggest a similar
newborn incidence of approximately 1/22 500 [12]. The
Table 2: Presentation data, GALT activity and mutation type of patients with galactosemia
Patient Year of diagnosis Age at Dx 
(months)
Race GALT activity*
Mutation
1 1980 0.1 W 3.0 Q188R / Q188R
2 1983 0.1 W 1.6 Q188R / Q188R
31 9 8 4 - ? 2 . 4 n d
41 9 8 4 6 . 5 B 0 . 2 n d
5 1985 4 B 4.2 S135L / S135L
6 1985 14.5 B 2.4 nd
71 9 8 5 - B 2 . 7 n d
81 9 8 6 2 . 5 M 3 . 5 n d
91 9 8 7 7 B 0 . 0 n d
10 1990 2 B 1.2 S135L / S135L
11 1991 0.3 M 0.0 Q188R / ?
12 1991 4 M 1.4 nd
13 1995 - M 3.8 S135L / S135L
14 1996 16 B 0.8 S135L / S135L
15** 1996 - B 3.5 S135L / S135L
16 1998 6 B 2.9 S135L / S135L
17 2001 2 M 2.2 S135L / S135L
18 2001 7 W 2.2 Q188R / Q188R
* Normal range of GALT activity: 12.5 to 65.0 U/gm of Hb (1 U = 1 µmol UDPG/hr) ** Clinical data unavailable B = Black (Negroid), M = Mixed 
ancestry, W = European ancestryBMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/7
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South African carrier frequencies for the S135L mutation
are the highest reported so far and represent a significant
concentration when contrasted with the frequency of 1/
505 reported in African Americans [20].
The projected figure for black newborns for the year 2000,
in the Cape Metropole was 25 920 (RE Dorrington, UCT,
Director Centre for Actuarial research); with the increasing
urbanisation of the Cape Metropole this figure is certain
to have increased in the subsequent years. This number
translates into expected referrals of at least 1–2 galactos-
emics every two years; current referral of 1 every 5 yrs is
significantly below this projection. Two opposing expla-
nations are likely to account for this diagnostic shortfall.
Patients, either go undetected and do not survive the neo-
natal period, or they do not present in the neonatal peri-
od. Some support for the latter explanation comes from
the finding that the S135L mutation can be associated
with a "mild" phenotype [8],[21], and it is conceivable
that only the severe end of the S135L/S135L presentation
spectrum, is attracting the attention of the medical frater-
nity in our region. It is likely that a measure of both pos-
sibilities is operative for our black patients.
The association of milder disease phenotypes with residu-
al enzyme activity is now well described in the metabolic
diseases literature. There are significant data to suggest
that this is also the case with the S135L mutation and ga-
lactosemia. Subjects homozygous for the S135L mutation,
although deficient in GALT activity in erythrocytes have
approx. 10% residual activity and enzyme mass in liver,
intestine and leucocytes [22],[23],[24]. This residual activ-
ity is also manifest by a whole body galactose oxidative ca-
pacity, which overlaps that of normal subjects when given
a tracer challenge of 13C-galactose [25]. Clinical parallels
would be the finding that S135L homozygotes have sur-
vived the neonatal period and have only been detected
when later problems such as cataracts, developmental de-
lay and poor school performance have been investigated
[22], and that S135L homozygotes detected in new born
screening programs appear to respond very well to dietary
restriction of lactose / galactose [8].
Conclusions
The true incidence of galactosemia in the South African
population is unknown, as newborn screening pro-
grammes have not been introduced. Reference laborato-
ries such as our own indicate that the disorder is rare and
probably has incidence data typical of those reported in
the USA except for black South Africans. Carrier preva-
lence data in the black population suggests that the true
incidence is much higher than that indicated by the num-
bers of patients referred for diagnostic workup. The reason
for this discrepancy is unknown but may involve a lack of
both detection and presentation in the neonatal period.
The delay in diagnosis revealed by our study indicates that
improved clinical vigilance may lower the age at detection
and improve the recognition of galactosemia in South Af-
rica. We are unable to comment on the post-diagnosis
clinical course of our S135L homozygotes as none were
maintained on a galactose free diet for any length of time
and all have been lost to follow up. We are also unable to
comment on indications that the S135L mutation has less
clinical impact than the Q188R mutation as most of our
S135L homozygotes were born into a rural primary
health-care environment and were thus diagnosed later
than our Q188R homozygotes. Further research should
focus on defining the phenotype / genotype relationships
in South African patients to determine whether a milder
clinical phenotype in S135L homozygotes does occur. Ad-
vances in understanding the pathogenesis of galactosemia
may ultimately explain why despite early appropriate die-
tary intervention many patients develop severe neurolog-
ical sequele and premature ovarian failure. Perhaps this
will lead to further improvements to the outcome of the
condition.
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